New combo aims to tackle tough uterine cancer

NCT ID NCT05559879

Recruiting now Disease control Sponsor: University of Alabama at Birmingham Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a combination of two drugs, cabozantinib and dostarlimab, in 37 women with recurrent gynecologic carcinosarcoma, a rare and aggressive cancer. The goal is to see if the combo can keep the cancer from growing for at least 6 months. Participants must have had at least one prior chemotherapy and have measurable tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: cabozantinib and dostarlimab
What this could lead to: If it works, this combination could offer a new treatment option for women with recurrent gynecologic carcinosarcoma, potentially slowing cancer growth.
What could go wrong: This is an early-phase trial with only 37 participants, so results may not apply broadly. The combination may cause side effects and might not improve survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

carcinoma endometrial cancer endometrium neoplasm female reproductive organ cancer uterine cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARCINOMA ENDOMETRIAL CANCER GYNECOLOGIC CANCER UTERINE CANCER

Contacts and locations

Locations

O'Neal Comprehensive Cancer Center at UAB
RECRUITING

Birmingham, Alabama, 35294, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.